Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Slides:

Advertisements

Similar presentations

Lung squamous cell carcinoma

Advertisements

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Michael F. Nentwich, MD, Benjamin A. Bohn, MD, Faik G

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma Arianna.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Survival of patients with distal esophageal and gastric cardia tumors: A population- based analysis of gastroesophageal junction carcinomas Bryan A. Whitson,

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Esophageal submucosa: The watershed for esophageal cancer

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Intrinsic cardiac stem cells are essential for regeneration

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Lower graft patency after off-pump than on-pump coronary artery bypass grafting: An updated meta-analysis of randomized trials Hisato Takagi, MD, PhD,

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma Yasuhiro Tsutani, MD, PhD, Yoshihiro.

The lord of the rings Antonio Miceli, MD, PhD

Invasive adenocarcinoma with bronchoalveolar features: A population-based evaluation of the extent of resection in bronchoalveolar cell carcinoma Bryan.

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Predictors of survival in lung torsion: A systematic review and pooled analysis Jie Dai, PhD, Dong Xie, MD, Haifeng Wang, MD, Wenxin He, MD, Yiming Zhou,

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: Prognostic comparison using.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Support Your Specialty

Clinical utility of CHADS2 and CHA2DS2-VASc scoring systems for predicting postoperative atrial fibrillation after cardiac surgery Su-Kiat Chua, MD,

Innovation and science: The future of valve design

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

A first start for lung transplantation?

Commentary: Tag, you're it

Navigating the lung for hidden treasure

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Yusuke Takahashi, MD, PhD, Prasad S. Adusumilli, MD

Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD

Niv Ad, MD, Lawrence M. Wei, MD

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Carcinoma of the esophagus: Prognostic significance of histologic type

Biomaterials for heart valve replacement: Conjectures and refutations

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Do statins delay the progression of aortic stenosis?

Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma.

“The more things change…”: The challenges ahead

Kiran H. Lagisetty, David G. Beer, Andrew C. Chang

Evaluating the best approach to treatment of aortic stenosis: The jury is still out Glen B. Taksler, PhD The Journal of Thoracic and Cardiovascular Surgery

Aritoshi Hattori, MD, Kenji Suzuki, MD

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

Apples remain apples NO matter what

Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non–small cell carcinoma Akira Iyoda, MD, Kenzo.

Presentation transcript:

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline Agorreta, PhD, Luis M. Montuenga, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 150, Issue 4, Pages 986-992.e11 (October 2015) DOI: 10.1016/j.jtcvs.2015.06.001 Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Evaluation of the prognostic capacity of the RNA metabolism signature in lung adenocarcinoma patients: (A) Relapse-free survival in the GSE31210 dataset; (B) Overall survival in the GSE31210 dataset; (C) Overall survival in the GSE13213 dataset. Patients were divided into low-, medium-, and high-risk groups based on the RNA metabolism score, as indicated in the Methods section. The P value of the log-rank test is shown in each graph. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Evaluation of the capacity of the RNA metabolism signature to predict overall survival in lung adenocarcinoma patients, separated by stages. Patients in the low-, medium-, and high-risk groups were combined from the separate analyses performed in the DCC, GSE31210, and GSE13213 datasets (n = 534). (A) Stage I (n = 398); (B) Stages II and III (n = 134); (C) Stage IA (n = 227); (D) Stage IB (n = 171). Patients were divided into low-, medium-, and high-risk groups based on the RNA metabolism score, as indicated in the Methods section. The P value of the log-rank test is shown in each graph. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Association between the prognostic capacity of the RNA metabolism signature and the benefit of adjuvant chemotherapy in lung adenocarcinoma patients of the DCC dataset. (A) Low-risk group of patients with stage I. (B) Medium-risk group of patients with stage I. (C) High-risk group of patients with stage I. (D) Low-risk group of patients with stage II or III. (E) Medium-risk group of patients with stage II or III. (F) High-risk group of patients with stage II or III. Patients without any events were censored at 60 months. Patients were divided into risk groups based on the RNA metabolism score, as indicated in the Methods section. The P value of the log-rank test is shown in each graph. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E1 Evaluation of the prognostic capacity of the RNA metabolism signature in lung squamous cell carcinoma patients: (A) Relapse-free survival in the GSE17710 dataset; (B) Overall survival in the GSE17710 dataset; (C) Overall survival in the GSE4573 dataset. Patients were divided into low-, medium-, and high-risk groups based on the RNA metabolism score, as indicated in the Methods section. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E2 Evaluation of the capacity of the RNA metabolism signature to predict relapse-free survival in lung adenocarcinoma patients of the DCC dataset, divided by stage: (A) Stage I; (B) Stages II/III; (C) Stage IA; (D) Stage IB. Patients without any events were censored at 60 months. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E3 Evaluation of the capacity of the RNA metabolism signature to predict overall survival in lung adenocarcinoma patients of the DCC dataset, divided by stage: (A) Stage I; (B) Stages II/III; (C) Stage IA; (D) Stage IB. Patients without any events were censored at 60 months. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E4 Evaluation of the capacity of the RNA metabolism signature to predict relapse-free survival in lung adenocarcinoma patients of the GSE31210 dataset, divided by stage: (A) Stage I; (B) Stage II; (C) Stage IA; (D) Stage IB. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E5 Evaluation of the capacity of the RNA metabolism signature to predict overall survival in lung adenocarcinoma patients of the GSE31210 dataset, divided by stage: (A) Stage I; (B) Stage II; (C) Stage IA; (D) Stage IB. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E6 Evaluation of the capacity of the RNA metabolism signature to predict overall survival in lung adenocarcinoma patients of the GSE13213 dataset, divided by stage: (A) Stage I; (B) Stages II/III; (C) Stage IA; (D) Stage IB. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure E7 Association between the prognostic capacity of the RNA metabolism signature and the benefit of adjuvant chemotherapy in lung adenocarcinoma patients of the DCC dataset: (A) Low-risk group; (B) Medium-risk group; (C) High-risk group. Patients without any events were censored at 60 months. Patients were divided into risk groups based on the RNA metabolism score as indicated in the Methods section. The P value of the log-rank test is shown in each graph. CI, Confidence interval. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

The RNA score accurately predicts overall survival in stage IB lung adenocarcinoma patients. The Journal of Thoracic and Cardiovascular Surgery 2015 150, 986-992.e11DOI: (10.1016/j.jtcvs.2015.06.001) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions